Exploring two two-edged swords

Radiation Research

Volumn 178, Issue 1, 2012, Pages 7-16

  Brenner, David J ^a  

^a Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOSENSITIZING AGENT;

ACADEMIC ACHIEVEMENT; ARTICLE; BIOLOGY; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CELL HYPOXIA; CELL KILLING; CELL PROLIFERATION; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DNA REPAIR; DOSIMETRY; EPIDEMIOLOGY; HUMAN; IN VITRO STUDY; INTENSITY MODULATED RADIATION THERAPY; LIFE EXPECTANCY; MEDICAL EDUCATION; META ANALYSIS (TOPIC); MOLECULARLY TARGETED THERAPY; NEGATIVE PI MESON THERAPY; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICS; PRIORITY JOURNAL; PROSTATE CANCER; PROTON THERAPY; RADIATION DOSE FRACTIONATION; RADIATION INDUCED NEOPLASM; RADIOBIOLOGY; RADIOSENSITIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); ROBOTICS; TREATMENT RESPONSE; TUMOR GROWTH; X RAY;

ANIMALS; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; NEOPLASMS, RADIATION-INDUCED; RADIOBIOLOGY; RADIOTHERAPY; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 84864481184     PISSN: 00337587     EISSN: 19385404     Source Type: Journal    
DOI: 10.1667/RR3085.1     Document Type: Article

References (53)

1. Cologne JB, Preston DL. Longevity of atomic-bomb survivors. Lancet 2000; 356:303-7.
2. Wintz H. Basic principles for successful Roentgen therapy of carcinoma. Radiology 1938; 30:35-42.
3. Regaud C, Ferroux R. Discordances des effets des rayons X, d'une part dans les peau, d'autre part dans les testicule, par le fractionnement de la dose: Diminution de l'efficacité dans le peau, maintien de l'efficacité dans le testicule. Compt Rend Soc Biol 1927; 97:431-4.
4. Coutard H. The results and methods of treatment of cancer by radiation. Ann Surg 1937; 106:584-98.
5. Gerweck LE, Zaidi ST, Zietman A. Multivariate determinants of radiocurability. I: Prediction of single fraction tumor control doses. Int J Radiat Oncol Biol Phys 1994; 29:57-66.
6. Fertil B, Malaise EP. Inherent cellular radiosensitivity as a basic concept for human tumor radiotherapy. Int J Radiat Oncol Biol Phys 1981; 7:621-9.
7. Leborgne F, Leborgne JH, Fowler J, Zubizarreta E, Mezzera J. Accelerated hyperfractionated irradiation for advanced head and neck cancer: effect of shortening the median treatment duration by 13 days. Head Neck 2001; 23:661-8.
8. Akagi Y, Hirokawa Y, Kagemoto M, Matsuura K, Ito A, Fujita K, et al. Optimum fractionation for high-dose-rate endoesophageal brachytherapy following external irradiation of early stage esophageal cancer. Int J Radiat Oncol Biol Phys 1999; 43:525-30.
9. Thames HD, Hendry JH. Fractionation in Radiotherapy. London and New York: Taylor & Francis; 1987.
10. Duchesne GM, Peters LJ. What is the a/b ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 1999; 44:747-8.
11. Thames HD, Jr., Withers HR, Peters LJ, Fletcher GH. Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships. Int J Radiat Oncol Biol Phys 1982; 8:219-26.
12. Barendsen GW. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys 1982; 8:1981-97.
13. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999; 43:1095-101.
14. Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP. Direct evidence that prostate tumors show high sensitivity to fractionation (low a/b ratio), similar to lateresponding normal tissue. Int J Radiat Oncol Biol Phys 2002; 52:6-13.
15. Proust-Lima C, Taylor JM, Secher S, Sandler H, Kestin L, Pickles T, et al. Confirmation of a low alpha/beta ratio for prostate cancer treated by external beam radiation therapy alone using a posttreatment repeated-measures model for PSA dynamics. Int J Radiat Oncol Biol Phys 2011; 79:195-201.
16. Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dosefractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: alpha/beta¼1. 4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys 2012; 82:e17-24.
17. Yeoh EE, Botten RJ, Butters J, Di Matteo AC, Holloway RH, Fowler J. Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int J Radiat Oncol Biol Phys 2011; 81:1271-8.
18. Arcangeli S, Strigari L, Gomellini S, Saracino B, Petrongari MG, Pinnaro P, et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys Epub 2012.
19. Pollack A, Walker G, Buyyounouski MK, Horowitz E, Price R, Feigenberg S, et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2011; 81:S1.
20. Dearnaley D, Syndikus I, Sumo G, Bidmead M, Bloomfield D, Clark C, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 2012; 13:43-54.
21. Kuban DA, Nogueras-Gonzalez GM, Hamblin L, Lee AK, Choi S, Frank SJ, et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. Int J Radiat Oncol Biol Phys 2010; 78:S58-9.
22. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003; 300:1155-9.
23. Park HJ, Griffin RJ, Hui S, Levitt SH, Song CW. Radiationinduced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat Res 2012; 177:311-27.
24. Brenner DJ, Curtis RE, Hall EJ, Ron E. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 2000; 88:398-406.
25. Gray LH, Radiation biology and cancer. In: Cellular Radiation Biology; A symposium considering radiation effects in the cell and possible implications for cancer therapy, a collection of papers. Baltimore: William and Wilkins; 1965. p. 8-25.
26. Sachs RK, Brenner DJ. Solid tumor risks after high doses of ionizing radiation. Proc Natl Acad Sci USA 2005; 102:13040-5.
27. Sachs RK, Wolfe AM. Perturbations of a cosmological model and angular variations of the microwave background. Astrophys J 1967; 147:73-90.
28. Stoeger WR, Ellis GF, Xu C. Observational cosmology. VI. The microwave background and the Sachs-Wolfe effect. Phys Rev D Part Fields 1994; 49:1845-53.
29. Hall EJ, Wuu CS. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 2003; 56:83-8.
30. Fowler PH, Perkins DH. The possibility of therapeutic applications of beams of negative pi-mesons. Nature 1961; 189:524-8.
31. Elwood JM. The design of clinical trials comparing pi-meson therapy with conventional radiotherapy. J Can Assoc Radiol 1979; 30:79-82.
32. Brenner DJ, Dicello JF, Zaider M. An interpretation of some biological results obtained in range-modulated negative pion beams. Int J Radiat Oncol Biol Phys 1982; 8:121-6.
33. Konski A, Speier W, Hanlon A, Beck JR, Pollack A. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? J Clin Oncol 2007; 25:3603-8.
34. Goitein M, Cox JD. Should randomized clinical trials be required for proton radiotherapy? J Clin Oncol 2008; 26:175-6.
35. Brenner DJ, Hall EJ. Secondary neutrons in clinical proton radiotherapy: A charged issue. Radiother Oncol 2008; 86:165-70.
36. Knapp EA, Swenson DA. The Los Alamos Scientific Laboratory ion linear accelerator program. Int J Radiat Oncol Biol Phys 1977; 3:383-5.
37. Schippers JM, Lomax AJ. Emerging technologies in proton therapy. Acta Oncol 2011; 50:838-50.
38. Overgaard J. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck-a systematic review and metaanalysis. Radiother Oncol 2011; 100:22-32.
39. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: New estimates of drug development costs. J Health Econ 2003; 22:151-85.
40. Bates TD, Peters LJ. Dangers of the clinical use of the NSD formula for small fraction numbers. Br J Radiol 1975; 48:773.
41. Thames HD, Jr., Peters LJ, Withers HR, Fletcher GH. Accelerated fractionation vs hyperfractionation: rationales for several treatments per day. Int J Radiat Oncol Biol Phys 1983; 9:127-38.
42. Baujat B, Bourhis J, Blanchard P, Overgaard J, Ang KK, Saunders M, et al. Hyperfractionated or accelerated radiotherapy for head and neck cancer. Cochrane Database Syst Rev 2010:CD002026.
43. Brenner DJ, Hall EJ, Huang Y, Sachs RK. Optimizing the time course of brachytherapy and other accelerated radiotherapeutic protocols. Int J Radiat Oncol Biol Phys 1994; 29:893-901.
44. Peters LJ. The ESTRO Regaud lecture. Inherent radiosensitivity of tumor and normal tissue cells as a predictor of human tumor response. Radiother Oncol 1990; 17:177-90.
45. Mackay RI, Hendry JH. The modelled benefits of individualizing radiotherapy patients' dose using cellular radiosensitivity assays with inherent variability. Radiother Oncol 1999; 50:67-75.
46. Brock WA, Tucker SL, Geara FB, Turesson I, Wike J, Nyman J, et al. Fibroblast radiosensitivity versus acute and late normal skin responses in patients treated for breast cancer. Int J Radiat Oncol Biol Phys 1995; 32:1371-9.
47. West CM. Invited review: intrinsic radiosensitivity as a predictor of patient response to radiotherapy. Br J Radiol 1995; 68:827-37.
48. Radack KL, Pinney SM, Livingston GK. Sources of variability in the human lymphocyte micronucleus assay: a population-based study. Environ Mol Mutagen 1995; 26:26-36.
49. Bonassi S, Fenech M, Lando C, Lin YP, Ceppi M, Chang WP, et al. HUman MicroNucleus project: international database comparison for results with the cytokinesis-block micronucleus assay in human lymphocytes: I. Effect of laboratory protocol, scoring criteria, and host factors on the frequency of micronuclei. Environ Mol Mutagen 2001; 37:31-45.
50. Sturgeon C, Hill R, Hortin GL, Thompson D. Taking a new biomarker into routine use-a perspective from the routine clinical biochemistry laboratory. Proteomics Clin Appl 2010; 4:892-903.
51. Garty G, Chen Y, Salerno A, Turner H, Zhang J, Lyulko O, et al. The RABiT: a rapid automated biodosimetry tool for radiological triage. Health Phys 2010; 98:209-17.
52. Garty G, Chen Y, Turner HC, Zhang J, Lyulko OV, Bertucci A, et al. The RABiT: a rapid automated biodosimetry tool for radiological triage. II. Technological developments. Int J Radiat Biol 2011; 87:776-90.
53. Merton RK. On the shoulders of giants. Chicago: University of Chicago Press; 1965.